Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada

Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada

Apr 27, 2017
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-expands-global-collaboration-amgen-commercialize-first-class-amg-334-erenumab-program-migraine-prevention-us-and-canada-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-expands-global-collaboration-amgen-commercialize-first-class-amg-334-erenumab-program-migraine-prevention-us-and-canada-0